Page last updated: 2024-09-02

tadalafil and cyclin d1

tadalafil has been researched along with cyclin d1 in 1 studies

Compound Research Comparison

Studies
(tadalafil)
Trials
(tadalafil)
Recent Studies (post-2010)
(tadalafil)
Studies
(cyclin d1)
Trials
(cyclin d1)
Recent Studies (post-2010) (cyclin d1)
1,7423921,08910,885705,157

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abadi, AH; Chang, WC; Chen, X; Clapper, ML; Gary, BD; Grizzle, WE; Gurpinar, E; Keeton, AB; Li, N; Li, Y; Moyer, MP; Piazza, GA; Tinsley, HN; Xi, Y; Zhu, B1

Other Studies

1 other study(ies) available for tadalafil and cyclin d1

ArticleYear
Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Caco-2 Cells; Carbolines; Cell Line; Cell Proliferation; Colonic Neoplasms; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Cyclin D1; HCT116 Cells; HT29 Cells; Humans; Inhibitor of Apoptosis Proteins; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Sulindac; Survivin; Tadalafil; Wnt Signaling Pathway

2013